Publications

Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study

MD Open. 2024 Sep 20;10:e004318 doi: 10.1136/rmdopen-2024-004318

Kristensen LE,

Ng KJ,

Ngantcha M,

Morel J,

Lubrano E,

Tillett W,

Alten R,

Chandran V,

Martinez Ferrer À,

Zhu B,

Kennedy D,

Holzkämper T,

Gullick N,

Kronbergs A,

Fakhouri W,

de la Torre I,

McGonagle DG

Kristensen et al. compared 14 PsA drugs across five treatment classes, evaluating their real-world effectiveness over three months. Ixekizumab showed rapid effectiveness on joint disease activity and skin outcomes, performing better than IL-12/23i and IL-23i, and comparable to TNFi and JAKi. More patients with active psoriasis achieved minimal disease activity with Ixekizumab than other therapies.

Keywords:

• Efficacy,
• Interleukin-23,
• MTX,
• Ixekizumab,
• JAK

関節リウマチにおけるJAK阻害薬:バリシチニブの経験

J. Clin. Med. 2023;12(13):4527 doi 10.3390/jcm12134527

Taylor PC,

Laedermann C,

Alten R,

Feist E,

Choy E,

Haladyj E,

De La Torre I,

Richette P,

Finckh A,

Tanaka Y

This review by Taylor, et al. reviews the long-term safety and efficacy data for baricitinib. Results from several studies showed that baricitinib has greater efficacy and survival compared to TNF inhibitors, and that the rate of CDAI <10 for baricitinib-treated RA patients increased over the course of seven years. Data also showed that remission rates were higher in real-world evidence than in RCTs.

Keywords:

• JAK,
• Baricitinib,
• Review

リスク保有患者におけるバリシチニブの安全性: リウマチおよび皮膚科領域の臨床試験解析

Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w

Taylor PC,

Bieber T,

Alten R,

Witte T,

Galloway J,

Deberdt W,

Issa M,

Haladyj E,

De La Torre I,

Grond S,

Wollenberg A

Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.

Keywords:

• JAK,
• Baricitinib,
• Safety,
• Review

関節リウマチ患者においてバリシチニブは疾患活動性 に関連せず構造的破壊進行を抑制する抗リウマチ効果 を有する

Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/annrheumdis-2021-221323

Lopez-Romero P,

de la Torre I,

Haladyj E,

Aletaha D,

Smolen JS

Baricitinib reduces structural damage progression versus placebo with background MTX and/or MTX, even in patients with moderate or high disease activity.In patients with RA, TNFi, IL-6i and rituximab have been shown to uncouple the link between disease activity and radiographic progression such that patients are protected from structural damage progression even if remission/low disease activity is not achieved.As such, Lopez-Romero, et al. aimed to evaluate if baricitinib further enhances diseas...

Keywords:

• JAK,
• Baricitinib,
• Efficacy,
• Radiographic

バリシチニブの関節性肺疾患に対するリスク: 治験症例の報告

Rheumatol Ther. 2021 Jun 28. DOI: 10.1007/s40744-021-00332-w

Salvarani C,

Sebastiani M,

Dieude P,

Garcia M,

Deberdt W,

Rogai V,

de la Torre I,

Inciarte-Mundo J,

Balsa A

Findings from a descriptive clinical case report from clinical trials show that patients with RA, treated with baricitinib, are at low risk to developing non-infectious interstitial lung disease (ILD) during treatment.Salvarani, et al. used a descriptive, multicentric, retrospective cohort study of eight randomised trials and one long-term extension study to estimate the number of incident ILD cases reported. Their findings showed that the risk of developing non-infectious ILD during baricitinib...

Keywords:

• JAK,
• Baricitinib,
• Safety,
• Lung / ILD

バリシチニブは関節リウマチ患者の関節破壊進行を抑制 – 包括的レビュー

Arthritis Res Ther 2021;23(1):3.

Emery P,

Durez P,

Hueber AJ,

Ide la Torre I,

Larsson E,

Holzkämper T,

Tanaka Y

MRI studies have shown that BARI reduces joint inflammation and damage in patients with moderate-to-severe active RA. This review summarises the effects of BARI on structural joint damage progression and the mechanisms underlying these effects, using MRI data from across the clinical trial program. Early preclinical animal models showed a significant reduction in joint inflammation, ankle width, and bone resorption. Efficacy and safety of BARI have been confirmed in an extensive programme, inclu...

Keywords:

• JAK,
• Baricitinib,
• Radiographic,
• Review

ベースライン 抗CarbV抗体 と 抗MCV 抗体とメトトレキサートまた はバリシチニブで治療されたRA患者における治療反応性と画像 的進行の関連性: RA-BEGINのpost-hoc 解析

Arthritis Res Ther. 2020;22(1):193

López-Romero P,

Martinez-Gamboa L,

Bang H,

de la Torre I,

Holzkämper T,

Feist E

Autoantibodies associated with the onset of RA have gained attention in recent years as prognostic biomarkers. Though not used diagnostically, anti-CarbV (carbamylated vimentin) and anti-MCV (vimentin modified by citrullination) baseline titers are being investigated as predictors of treatment response. In this post-hoc analysis of data from the RA-BEGIN cohort of active RA patients, López-Romero and colleagues consider the potential predictive values of baseline anti-CarbV and anti-MCV titers r...

Keywords:

• JAK,
• Baricitinib,
• Efficacy,
• Bone,
• Radiographic

低疾患活動性のRA患者における疼痛緩和と機能改善に対するバ リシチニブとアダリムマブの効果: RA-BEAMからの探索的解析

J Clin Med. 2019 Sep 5;8(9). pii: E1394

Fautrel B,

Kirkham B,

Pope JE,

Takeuchi T,

Gaich C,

Quebe A,

Zhu B,

de la Torre I,

De Leonardis F,

Taylor PC

Post hoc analyses from RA-BEAM concluded that BARI 4 mg QD or ADA 40 mg Q2W resulted in improvements in pain, physical function, fatigue and work productivity in patients with RA, independent of the treatment’s impact on inflammation. Among patients achieving remission or LDA, greater improvements in pain and physical function were seen with BARI than with ADA or PBO.Of 1010 patients included in the analysis at Week 24, 168 were in remission, 310 were in remission/LDA and 700 were not in remissi...

Keywords:

• JAK,
• Baricitinib,
• Phase 3,
• Pain

活動性関節リウマチ患者におけるバリシチニブ開始時の既 往歴や併存症に基づく有効性と安全性データ

Ann Rheum Dis. 2019 Aug;78(8):1135-1138.

Combe B,

Balsa A,

Sarzi-Puttini P,

Tony HP,

de la Torre I,

Rogai V,

Durand F,

Witt S,

Zhong J,

Dougados M

In a post-hoc analysis, BARI 4 mg showed similar efficacy and safety during placebo-controlled and LTE observation periods regardless of the presence or absence of select comorbidities in RA patients.Patients with RA have a high prevalence of comorbidities. This post-hoc analysis investigated the effect of select comorbidities (depression, osteoporosis, hepatic, cardiovascular or pulmonary disorders) on the efficacy and safety of BARI 4 mg QD in patients with moderate-to-severe active RA and ina...

Keywords:

• JAK,
• Baricitinib,
• Efficacy,
• Safety

従来型抗リウマチ薬またはグココルチコイドで治療中関節リウマチ患者のバリシチニブの安全性を有効性

Rheumatol Ther 2018 Dec;5(2):525-536. DOI 10.1007/s40744-018-0128-0

van Vollenhoven R,

Helt C,

Arora V,

Zhong J,

Correia AP,

de la Torre I,

Muram D

Baricitinib (BARI) in combination with MTX and concomitant csDMARDs was shown to be efficacious, regardless of corticosteroid use in RA patients. MTX is prescribed to most RA patients but concomitant csDMARDs and/or corticosteroids can be added. This study assessed the efficacy and safety of BARI in two arms; with/without corticosteroids and; with MTX only/MTX plus csDMARD/csDMARDs only. Baseline characteristics and adverse reactions were also compared. Data were pooled from two phase 3 studies ...

Keywords:

• JAK,
• Baricitinib,
• Safety,
• Efficacy